Introduction
Obesity is a global problem; affecting estimated 300 million people world-wide its prevalence is increasing in both developed and developing countries throughout the world. [1] Obesity is a world-wide epidemic that is characterized by excess adipose tissue and that contributes to numerous chronic diseases and early mortality. [2] [3] [4] [5] This epidemic has received both national and international attention due to obesity's detrimental impact on health, the enormous economic burden it imposes and its increasing prevalence. [6] The present epidemic of overweight and obesity in the whole world is an unintended consequence of the economic, social and technological advances realized during the past several decades. [7] With the onset of the industrial revolution increase in the average body size of the population is an additional concern to health care professional. Now a day in fast pace life people are more inclined to food which low in cost, palatable and readily available in prepackaged
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Study design
This is a randomized controlled stratified, open level study.
Inclusion criteria

•
The patients age range between 20 Every patient was registered after fulfilling the inclusion criteria underwent assessment of symptoms and different components of weight, BMI, anthropometric parameters.
Follow-up study
A total of three follow-ups were done at the interval of 1 month each and all the subjective and objective parameter were recorded each time.
Study groups
Treatment schedule for Group I (n = 32)
In this group, Lekhaniya Kashaya Vasti was given to total 35 registered patients and out of 35 patient 32 completed the course.
Contents and preparation of the Lekhaniya Kashaya Vasti
It has been formulated from different Ayurvedic texts on the basis of their properties which are described under Sthaulya Chikitsa and its contents are as fol1ows: 
Duration
This procedure was repeated once in every month consecutively for period of 3 months.
Treatment schedule for Group II (n = 33)
To this group, the Pathya Ahara-Vihara was given and out of 35 registered patients 33 completed the course. General scheme of Pathya which was advised to the patients [ Table 1 ].
The calorific value of this diet was estimated. It provides 800-1100 kcal/day with 9 g fibers, 40 g fat, 50 g protein and 100 g carbohydrate.
Energy consuming practices in Pathya groups
Patients were advised to practice regular exercise. Here are some specific energy consuming practices in Pathya group (as per the Ayurverdic texts). The assessment was carried out before starting the treatment and at each 3 follow-ups of 30 days and the improvement was assessed on the basis of percentage relief and statistical evaluations.
Morning
Clinical assessment of the disease
Criteria for assessment of overall effects
For the gross assessment of the result obtained with the clinical trial, the response of the treatment was determined in terms of:
Subjective improvement
Patients were specifically asked about feeling of well-being and improvement in Angachalatva, Atishudha, and Kshudra Shwasa at each follow-up of treatment.
Clinical improvement
Reduction in weight, BMI, arm circumference, Waist Hip Ratio (WHR) was noted at each follow-up.
Hematological and biochemical assessment
Lipid profile, liver function test value was recorded before and after the treatment in registered cases to evaluate the nature and extent of change in relation to course of disease. Hemoglobin in g%, total leucocytes counts, differential leucocytes counts, Erythrocyte Sedimentation Rate (ESR), serum creatinine, blood urea and blood sugar values were recorded before and after the treatment in registered cases to evaluate the safety profile of the drug.
Statistical analysis
The data collected were transferred on master chart showing various items/variables in columns and subjects in rows. The analysis of data was performed using statistical software SPSS version 16 and it is developed by International Business Machines Corporation. Tables 4 and 5 ].
In the present clinical study statistically no change was observed in blood urea, blood sugar, serum creatinine and liver function test after trial therapy. Significant mean reduction was observed in serum Low-Density Lipoprotein (LDL), serum triglycerides, Very Low Density Lipoprotein (VLDL) and cholesterol level in I group than Group II, whereas in level of serum High-Density Lipoprotein (HDL) no significant change was observed after trial therapy in both the groups [ Tables 6 and 7 ]. Safety profile of the drug serum bilirubin, serum glutamic oxaloacetic transaminase, serum glutamic-pyruvic transaminase, alkaline phosphate, serum creatinine and blood urea, there was no 
Intra-group (within the group) comparison
To test the significance of mean of difference of paired observations (before treatment v/s after treatment) paired t-test was applied.
Inter-group comparison (between the groups)
In case of more than two independent groups, one-way analysis of variance was applied and value of F test was determined, whenever F test resulted statistically significant, post-hoc test was applied for multiple comparisons, identifying significant pairs of groups.
Results
In symptoms like Angachalatva, significant mean reduction was observed and inter group comparison was not significant whereas in Kshudra Shwasa, Gatrasada, Atipipasa symptoms significant mean reduction was observed and Group I was more effective than Group II and on inter group comparison Group I was significant than Group II [ Tables 2 and 3 ]. Dravaya, obstruction of channels are broken down the and morbid material from all over the body are expelled out, thus breaks the pathogenesis of disease Sthaulya (obesity) [8] • Vasti help in Vatanulomana by Tikta (bitter), Katu (astringent) Rasa (taste) and Tikshna Guna present in trial drug, thus helps in the correction of passage of Apana Vayu and these qualities irritate the intestine leading to increased contraction of intestine hence provides less time for absorption of fat from intestine. Vasti therapy may be stimulator for many intraluminal, luminal and whole body function [9] • Trial drug possess cholagogue property, Tikta, Katu Rasa, Tikshna properties irritate the intestine leading to increased propulsive movement of intestine. [10] Hence, provides less time for absorption of fat from intestine • Dravyas present in the trial drug possess choleretics action which causes excretion of bile which further leads to decrease absorption of fat from intestine [10] • Trial drug has, Kutki, have irritant property which damage the structure of villi in intestine hence causes decreased capacity for absorption [11] • Sesamum oil has Katu and Tikta Rasa property. Due to this, it reduces excessive Meda of the body. It also contain Agnideepaka and Vata Nashak property. Agnideepaka property enhances the Jathragni as well as Dhatwagni.
Excessive Abaddha Meda will change in Baddha Meda due enhancement of Jatharagni [12] • Tikshna Guna acts on Srotas (channels) immediately and pierces the smallest cells of the vessels and removes the obstruction caused by lipids. [13] These Gunas also activate the Jatharagni and Dhatvagni and maintain their status. [14] Tikta, Katu Rasa, Laghu, Ushana properties present in trial drug are very useful for Ama Pachana, so by means of these properties digestion of Ama, restoration of [15, 16] Tikta and Kashaya Rasas have Lekhana Guna that scraps out excessive Kapha and Meda from srotas. In addition to Lekhana, Kashaya Rasa also has the property of Shoshana [17, 18] which absorbs the excessive fluids and lipid substances caused by hypercholesterolaemia. Laghu Guna acts as Kaphahara, reduces the tissue weights (Langhana) [15, 19] and clears the channels of the body (Srotoshodhana). All Dravyas are Ushna in Virya, which oppose any increment of Kapha and Medas by the Vilayan property. [18, 20] 
Conclusion
In present clinical study, significant reduction in BMI and WHR was seen in Group I as compared to Group II. The Lekhaniya Kashaya Vasti is effective (P < 0.001) for weight reduction. Hence, it can be concluded that trial drug is a very good combination fo r Medoghna activity. 
